KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Common Equity (2016 - 2025)

Boston Scientific (BSX) has disclosed Common Equity for 17 consecutive years, with $24.5 billion as the latest value for Q4 2025.

  • Quarterly Common Equity rose 12.41% to $24.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.5 billion through Dec 2025, up 12.41% year-over-year, with the annual reading at $24.5 billion for FY2025, 12.41% up from the prior year.
  • Common Equity hit $24.5 billion in Q4 2025 for Boston Scientific, up from $23.6 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $24.5 billion in Q4 2025 to a low of -$2.3 billion in Q4 2021.
  • Historically, Common Equity has averaged $9.8 billion across 5 years, with a median of $8.4 billion in 2021.
  • Biggest five-year swings in Common Equity: surged 2704.0% in 2023 and later crashed 230.77% in 2025.
  • Year by year, Common Equity stood at -$2.3 billion in 2021, then soared by 66.68% to -$750.0 million in 2022, then soared by 2704.0% to $19.5 billion in 2023, then rose by 11.47% to $21.8 billion in 2024, then rose by 12.41% to $24.5 billion in 2025.
  • Business Quant data shows Common Equity for BSX at $24.5 billion in Q4 2025, $23.6 billion in Q3 2025, and -$17.0 million in Q2 2025.